WR279,396, a Third Generation Aminoglycoside Ointment for the Treatment of Leishmania major Cutaneous Leishmaniasis: A Phase 2, Randomized, Double Blind, Placebo Controlled Study

• Afif Ben Salah ,

  Contributed equally to this work with: Afif Ben Salah, Pierre A. Buffet

  Affiliation Institut Pasteur de Tunis, Tunis, Tunisia

  ⨯
• Pierre A. Buffet ,

  Contributed equally to this work with: Afif Ben Salah, Pierre A. Buffet

  Affiliation Institut Pasteur, Paris, France

  ⨯
• Gloria Morizot,

  Affiliation Institut Pasteur, Paris, France

  ⨯
• Nathalie Ben Massoud,

  Affiliation Institut Pasteur de Tunis, Tunis, Tunisia

  ⨯
• Amor Zâatour,

  Affiliation Institut Pasteur de Tunis, Tunis, Tunisia

  ⨯
• Nissaf Ben Alaya,

  Affiliation Institut Pasteur de Tunis, Tunis, Tunisia

  ⨯
• Nabil Bel Haj Hamida,

  Affiliation Institut Pasteur de Tunis, Tunis, Tunisia

  ⨯
• Zaher El Ahmadi,

  Affiliation Direction Régionale de la Santé de Sidi Bouzid, Sidi Bouzid, Tunisia

  ⨯
• Matthew T. Downs,

  Affiliation Statistics Collaborative, Washington, D.C., United States of America

  ⨯
• Philip L. Smith,

  Affiliation United States Army Medical Materiel Development Activity, Fort Detrick, Maryland, United States of America

  ⨯
• Koussay Dellagi,

  Affiliation Institut Pasteur de Tunis, Tunis, Tunisia

  ⨯
• Max Grögl

  * E-mail: max.grogl1@us.army.mil

  Affiliation Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America

  ⨯